EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma

Ryan D Chow iD, Jessica B Long, Sirad Hassan, Stephanie B Wheeler, Lisa P Spees, Michael S Leapman, Michael E Hurwitz, Hannah D McManus, Cary P Gross iD, Michaela A Dinan iD

JNCI Cancer Spectrum · 2023

DOI: 10.1093/jncics/pkad036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2023. Verfasst von Ryan D Chow und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disparities in metastatic renal cell carcinoma (mRCC) outcomes persist in the era of oral anticancer agents (OAAs) and immunotherapies (IOs). We examined variation in the utilization of mRCC systemic therapies among US Medicare beneficiaries from 2015 to 2019. Logistic regression models evaluated the association between therapy receipt and demographic covariates including patient race, ethnicity, and sex. In total, 15 407 patients met study criteria. After multivariable adjustment, non-Hispanic Black race and ethnicity was associated with reduced IO (adjusted relative risk ratio [aRRR] = 0.76, 95% confidence interval [CI] = 0.61 to 0.95; P = .015) and OAA receipt (aRRR = 0.76, 95% CI = 0.64 to 0.90; P = .002) compared with non-Hispanic White race and ethnicity. Female sex was associated with reduced IO (aRRR = 0.73, 95% CI = 0.66 to 0.81; P < .001) and OAA receipt (aRRR = 0.74, 95% CI = 0.68 to 0.81; P < .001) compared with male sex. Thus, disparities by race, ethnicity, and sex were observed in mRCC systemic therapy utilization for Medicare beneficiaries from 2015 to 2019.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMaleFemaleAgedUnited StatesMedicareEthnicityWhite

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, CT, USA.
  • Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, CT, USA.
  • Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA.
  • Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA.
  • Department of Urology, Yale School of Medicine, New Haven, CT, USA.
  • Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Ryan D Chow, Cary P Gross, Michaela A Dinan

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIH/NCI

Zitieren

APA

Chow, R. D., Long, J. B., Hassan, S., Wheeler, S. B., Spees, L. P., Leapman, M. S., Hurwitz, M. E., McManus, H. D., Gross, C. P., & Dinan, M. A. (2023). Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkad036

Vancouver

Chow RD, Long JB, Hassan S, Wheeler SB, Spees LP, Leapman MS, et al. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum. 2023. doi:10.1093/jncics/pkad036

BibTeX
@article{Chow2023,
  author = {Chow, Ryan D and Long, Jessica B and Hassan, Sirad and Wheeler, Stephanie B and Spees, Lisa P and Leapman, Michael S and Hurwitz, Michael E and McManus, Hannah D and Gross, Cary P and Dinan, Michaela A},
  title = {Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma},
  journal = {JNCI Cancer Spectrum},
  year = {2023},
  doi = {10.1093/jncics/pkad036}
}
Kostenlos starten →